Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Fostamatinib (R788) binds and inhibits Syk kinase thus interfering with mast cell, macrophage, and B-cell activation as well as downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis (NCI drug dictionary)
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fostamatinib||Tavalisse||R788|R935788||SYK Inhibitor 15||Fostamatinib (R788) binds and inhibits Syk kinase thus interfering with mast cell, macrophage, and B-cell activation as well as downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RB1 inact mut||retinoblastoma||sensitive||Fostamatinib||Preclinical||Actionable||In a preclinical study, retinoblastoma cell lines demonstrated sensitivity to Fostamatinib resulting in cell death (PMID: 22237022).||22237022|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02611063||Phase I||Fostamatinib||Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant||Active, not recruiting||USA||0|
|NCT05030675||Phase I||Fostamatinib||Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents||Recruiting||USA||0|